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attended a Portuguese-speaking
school. Had the five years in Rio been
a brake on his education? “On the
contrary,” he says. “I was challenged
by having to continue my studies
while also learning the language.”
It hardly held him back. After
earning degrees in medicine and
biochemistry at Zurich, he went to
the US in 1961. At New York
University, he studied RNA phage
replication, focusing on the RNA
bacteriophage Qβ, which has only
4,300 nucleotides. (He remarks wryly
that much of the molecular biology of
Qβ remains unknown, and wonders
aloud how some researchers can talk
seriously about understanding
100,000 human genes.)
By 1967 he was back in Zurich,
heading the institute, and in 1978 he
and other leading molecular biologists
founded the company Biogen. As he
was already working in the institute
on the cloning of mouse interferon,
his group was commissioned by
Biogen to clone human interferon
cDNA. Success came unexpectedly
over Christmas 1979; Weissmann,
who had left the lab for a few days’
skiing with the family, recounts how
he heard the news in a call-box on top
of a mountain, before rushing back to
spend the rest of the holiday in the
lab. Although his time with Biogen
was enjoyable, 10 years were enough
and from the late 1980s he was ready
to concentrate again on basic research.
In fact, Weissmann not only
enjoys basic research but also feels
passionate about defending it. “One
should cultivate basic research as one
cultivates the arts,” he says — and, as
a fan of twentieth-century art and of
the work of members of the London
School, such as Francis Bacon, he is
better placed than many colleagues to
know what this means.
And his next project? Well, he
gives himself about five years in
London, then he will return to
Switzerland. “I think that would be a
good time to stop.” But will he?
Phyllida Brown is a science writer based
in London.
The amplification of
oncogenes in human
tumours is often
mediated by little bits of
extra-chromosomal DNA called
double-minute chromosomes (DMs).
If cancer cells lose these DMs, the
cells revert to a normal growth
pattern and become more susceptible
to chemotherapy.
The larger image above shows a
prometaphase spread of a cell from a
colon cancer cell line in which DMs
(containing c-myc oncogenes) have
been labelled yellow and
chromosomal DNA counterstained
red. Importantly, the DMs are not
distributed randomly; they cluster
around the periphery of the
prometaphase ring.
DMs can be removed from the
nucleus by a molecular mechanism
known as micronucleation, which is
initiated by nuclear budding during
S phase of the cell cycle. The inset
image shows one of
these nuclear buds (at
bottom right) in which
the DMs (yellow) have been
selectively entrapped. The rate of
micronucleation can be increased by
the addition of replication inhibitors
and, in normal human cells, is
increased by inactivating the tumour
suppressor p53. Such studies might
help in the development of new
strategies to encourage tumour cells
to revert to normal growth by getting
rid of their DMs.
For further details, see J Cell Biol
1998, 140:1307-1320 and Curr Biol
1998, 8:377-385. Images reproduced
with permission from J Cell Biol and
provided by N. Shimizu, Faculty of
Integrated Arts and Sciences,
Hiroshima University, Kagamiyama
1-7-1, Higashi-Hiroshima 739-8521,
Japan and G. Wahl, The Salk
Institute, 10010 North Torrey Pines
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